(Q27349020)
Statements
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors (English)
0 references
2009
0 references
4
0 references
5
0 references
e5717
0 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference